Search Results - "Vasquez, J Gabriel"

Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis by Bhatia, Neal, Heim, Jayme, Schenkel, Brad, Vasquez, J. Gabriel

“…Tildrakizumab is an anti-interleukin-23 p19 monoclonal antibody approved for the treatment of adults with moderate-to-severe plaque psoriasis. Little…”
Get full text

Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis in a real-world setting by Bhatia, Neal, Heim, Jayme, Vasquez, J Gabriel, Bhutani, Tina, Schenkel, Brad, Gogineni, Ranga, Koo, John

“…Tildrakizumab is an anti-interleukin-23 p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. This report describes final…”
Get full text

Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis by Bhutani, Tina, Koo, John, Heim, Jayme, Bhatia, Neal, Mathew, Jacob, Ferro, Thomas, Vasquez, J. Gabriel

“…Introduction Plaque psoriasis is a chronic condition that may impact patients’ work productivity. Tildrakizumab, an interleukin-23 p19 inhibitor, is approved…”
Get full text

Neocortical and Thalamic Spread of Amygdala Kindled Seizures by Blumenfeld, Hal, Rivera, Maritza, Vasquez, J. Gabriel, Shah, Akash, Ismail, Dina, Enev, Miro, Zaveri, Hitten P.

“…Purpose: Amygdala kindling is an epilepsy model involving long‐term network plasticity in the nervous system. In this model, repeated weak stimulation of the…”
Get full text

Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis by Heim, Jayme, Vasquez, J Gabriel, Bhutani, Tina, Koo, John, Mathew, Jacob, Gogineni, Ranga, Ferro, Thomas, Bhatia, Neal

“…Tildrakizumab is a humanized anti-interleukin-23 p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. This report…”
Get more information

Alteration of Neuropilin‑1 and Heparan Sulfate Interaction Impairs Murine B16 Tumor Growth by Painter, Chelsea D., Sankaranarayanan, Nehru Viji, Nagarajan, Balaji, Mandel Clausen, Thomas, West, Alan M.V., Setiawan, Nicollette J., Park, Jeeyoung, Porell, Ryan N., Bartels, Phillip L., Sandoval, Daniel R., Vasquez, Gabriel J., Chute, John P., Godula, Kamil, Vander Kooi, Craig W., Gordts, Philip L.S.M., Corbett, Kevin D., Termini, Christina M., Desai, Umesh R., Esko, Jeffrey D.

“…Neuropilin-1 acts as a coreceptor with vascular endothelial growth factor receptors to facilitate binding of its ligand, vascular endothelial growth factor…”
Get full text

42290 Patients’ quality of life in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis by Heim, Jayme, Vasquez, J Gabriel, Rozzo, Stephen J., Schenkel, Brad, Bhatia, Neal

Get full text

42295 Safety of tildrakizumab in a Phase 4 real-world study in patients with moderate-to-severe plaque psoriasis by Vasquez, J Gabriel, Bhatia, Neal, Schenkel, Brad, Rozzo, Stephen J., Heim, Jayme

Get full text

42293 Real-world effectiveness of tildrakizumab in a Phase 4 study in patients with moderate-to- severe plaque psoriasis by Bhatia, Neal, Vasquez, J Gabriel, Schenkel, Brad, Rozzo, Stephen J., Heim, Jayme

Get full text

42281 Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis by Bhatia, MD, Neal, Vasquez, J Gabriel, Schenkel, Brad, Rozzo, Stephen J., Heim, Jayme

Get full text

33129 Real-world effectiveness and safety of tildrakizumab in patients with moderate to severe plaque psoriasis: Week 28 interim analysis of a phase 4 study by Bhatia, Neal, Heim, Jayme, Torres, Monique, Beute, Paulita, Rozzo, Stephen J., Vasquez, J. Gabriel

Get full text

33133 A phase 4, real-world study of tildrakizumab in moderate to severe psoriasis: Week 28 interim analysis by Heim, Jayme, Vasquez, J. Gabriel, Beute, Paulita, Torres, Monique, Rozzo, Stephen J., Bhatia, Neal

Get full text

Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe plaque psoriasis by Bhatia, Neal, Vasquez, J Gabriel, Schenkel, Brad, Heim, Jayme

Get full text

Patients’ quality of life in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis by Heim, Jayme, Vasquez, J Gabriel, Schenkel, Brad, Bhatia, Neal

Get full text

Molecular Interaction of Neuropilin‐1 and 3‐O‐sulfated Heparan Sulfate Modulates Angiogenesis‐dependent Tumor Growth by Painter, Chelsea D., Clausen, Thomas M., Park, Jeeyoung, Vasquez, Gabriel J., Liu, Jian, Gordts, Philip L.S.M., Esko, Jeffrey D.

“…Abstract only Neuropilin‐1 (Nrp1) acts as a coreceptor with Vascular Endothelial Growth Factor Receptor (VEGFR) to facilitate binding of its ligand, Vascular…”
Get full text

The depressed frail phenotype as a risk factor for mortality in older adults: A prospective cohort in Peru by Vasquez-Goñi, Gabriel A.J., Papuico-Romero, Basilio M., Urrunaga-Pastor, Diego, Runzer-Colmenares, Fernando M., Parodi, José F.

“…Frailty and depression can coexist as depressed frail phenotype, useful for the comprehensive evaluation of older adults and prevention of adverse outcomes…”
Get full text